WHO Advises Against Use of Two Drugs for Non-Severe COVID-19
Current evidence does not justify using colchicine to treat non-severe illness, and fluvoxamine shouldn’t be used outside of clinical trials.
The antidepressant drug fluvoxamine and the gout drug colchicine are not recommended for patients with mild or moderate covid-19 because there is currently insufficient evidence that they improve important outcomes for patients, and both drugs carry potential harms, say a WHO Guideline Development Group (GDG) panel of international experts in The BMJ today.
No recommendation was made for either drug in patients with severe or critical illness, given limited or no data.
Fluvoxamine and colchicine ...